Research progress on the correlation between transforming growth factor-ß level and symptoms of depression. / è½¬åŒ–ç”Ÿé•¿å› å­-ßæ°´å¹³ä¸ŽæŠ‘éƒç—‡ç–—æ•ˆç›¸å ³.

Transforming growth factor (TGF)-ß is a group of cytokines with anti-inflammatory effects in the TGF family, which participates in the development of stress and depression-related mechanisms, and plays roles in the regulation of inflammatory response in depression and the recovery of various cytokine imbalances. The core symptoms of depression is associated with TGF-ß level, and the psychological symptoms of depression are related to TGF-ß gene polymorphism. Various antidepressants may up-regulate TGF-ß level through the complex interaction between neurotransmitters and inflammatory factors, inhibiting inflammatory response and regulating cytokine imbalance to improve depressive symptoms. Studies have shown that recombinant TGF-ß1 protein has beneficial effects in mouse depression models, indicating TGF-ß1 might be a potential therapeutic target for depression and nasal sprays having the advantage of being fast acting delivery method. This article reviews the research progress on dynamic changes of TGF-ß level before and after depression treatment and the application of TGF-ß level as an indicator for the improvement of depressive symptoms. We provide ideas for the development of new antidepressants and for the evaluation of the treatment efficacy in depression.